SWOG clinical trial number
SWOG-9235
Phase II Trial of Casodex in Advanced Prostate Cancer Patients Who Failed Conventional Hormonal Manipulation
Closed
Phase
Accrual
96%
Published
Abbreviated Title
Phase II Trial of Casodex in Advanced Prostate Cancer Patients Who Failed Conventional Hormonal Manipulation
Activated
12/15/1993
Closed
06/01/1994
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
2001
Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235)
2000
Behavioral science research in the cooperative group setting: the Southwest Oncology Group Experience
1996
Phase II trial of casodex in advanced prostate cancer (CaP) patients who failed conventional hormonal manipulation: A Southwest Oncology Group (SWOG) study (SWOG9235).
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase